REIMBURSEMENT FOR RADIO/MICROWAVE-BASED BPH TREATMENTS KEY TO WIDESPREAD USE; INSURERS LIKELY TO TIE COVERAGE DECISIONS TO PUBLICATION OF DURABILITY DATA

Widespread acceptance by the urology community, particularly office-based physicians, of less-invasive technology for treatment of benign prostatic hyperplasia (BPH) hinges on favorable reimbursement decisions by insurance companies and the Health Care Financing Administration, a four-member panel of urologists told attendees of an Oct. 30 Dain Bosworth urology symposium in Boston.